Oct 11, 2019 08:00AM
Oct 11, 2019 08:00AM
Oct 10, 2019 08:05AM
Oct 10, 2019 08:01AM
Oct 10, 2019 08:01AM
Sep 16, 2019 05:54AM
Sep 16, 2019 01:55AM Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
Sep 16, 2019 01:55AM
Sep 5, 2019 04:01PM
Sep 5, 2019 04:01PM
Sep 4, 2019 09:00AM
Aug 28, 2019 04:01PM
Aug 28, 2019 04:01PM
Aug 6, 2019 04:07PM Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
Aug 6, 2019 04:07PM
Aug 1, 2019 08:01AM
Aug 1, 2019 08:01AM
Jul 30, 2019 04:01PM
Jul 30, 2019 04:01PM
Jul 11, 2019 08:03AM
Jul 11, 2019 08:00AM Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention
Jul 11, 2019 08:00AM
Jul 8, 2019 08:00AM
Jul 8, 2019 08:00AM
May 8, 2019 08:00AM
May 8, 2019 08:00AM
May 6, 2019 08:10AM
May 6, 2019 08:00AM Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials
May 6, 2019 08:00AM
May 2, 2019 04:05PM
May 2, 2019 04:05PM
Apr 26, 2019 04:05PM
Apr 26, 2019 04:05PM
Apr 23, 2019 09:24AM
Apr 23, 2019 08:00AM Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology
Apr 23, 2019 08:00AM
Apr 22, 2019 06:06PM
Apr 22, 2019 04:35PM
Apr 22, 2019 04:34PM
Apr 22, 2019 04:34PM
Feb 25, 2019 04:05PM
Feb 25, 2019 04:05PM Alder BioPharmaceuticals® Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Feb 22, 2019 08:02AM
Feb 22, 2019 08:00AM
Feb 22, 2019 08:00AM
Jan 17, 2019 04:01PM
Jan 17, 2019 04:01PM
Nov 5, 2018 04:08PM
Nov 5, 2018 04:08PM Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results
Oct 23, 2018 08:02AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All